Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACOR

Acorda Therapeutics (ACOR) Stock Price, News & Analysis

Acorda Therapeutics logo

About Acorda Therapeutics Stock (NASDAQ:ACOR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.66
$15.60
52-Week Range
N/A
Volume
416,900 shs
Average Volume
119,299 shs
Market Capitalization
$820 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Acorda: I did not accept money from Guo
See More Headlines

ACOR Stock Analysis - Frequently Asked Questions

Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) earnings per share for the quarter, beating the consensus estimate of ($31.20) by $2.60. The biopharmaceutical company earned $31.46 million during the quarter, compared to analysts' expectations of $30.57 million. Acorda Therapeutics had a negative trailing twelve-month return on equity of 2,206.93% and a negative net margin of 214.95%.

Acorda Therapeutics shares reverse split on the morning of Monday, June 5th 2023.The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acorda Therapeutics investors own include Meta Platforms (META), Sangamo Therapeutics (SGMO), GE Aerospace (GE), NVIDIA (NVDA), Exxon Mobil (XOM), Energy Transfer (ET) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
11/09/2021
Today
7/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACOR
Employees
111
Year Founded
1995

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$252.85 million
Net Margins
-214.95%
Pretax Margin
-251.65%

Debt

Sales & Book Value

Annual Sales
$117.63 million
Price / Cash Flow
0.02
Book Value
($127.17) per share
Price / Book
N/A

Miscellaneous

Free Float
1,210,000
Market Cap
$820 thousand
Optionable
No Data
Beta
1.40

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ACOR) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners